These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 9624481)
1. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Klepser ME; Ernst EJ; Ernst ME; Messer SA; Pfaller MA Antimicrob Agents Chemother; 1998 Jun; 42(6):1387-91. PubMed ID: 9624481 [TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Pfaller MA; Messer SA; Coffman S Antimicrob Agents Chemother; 1997 Apr; 41(4):763-6. PubMed ID: 9087485 [TBL] [Abstract][Full Text] [Related]
3. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Ernst ME; Klepser ME; Wolfe EJ; Pfaller MA Diagn Microbiol Infect Dis; 1996; 26(3-4):125-31. PubMed ID: 9078447 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Moore CB; Oakley KL; Denning DW Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Ernst EJ; Roling EE; Petzold CR; Keele DJ; Klepser ME Antimicrob Agents Chemother; 2002 Dec; 46(12):3846-53. PubMed ID: 12435687 [TBL] [Abstract][Full Text] [Related]
7. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. Arévalo MP; Carrillo-Muñoz AJ; Salgado J; Cardenes D; Brió S; Quindós G; Espinel-Ingroff A J Antimicrob Chemother; 2003 Jan; 51(1):163-6. PubMed ID: 12493803 [TBL] [Abstract][Full Text] [Related]
8. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Marco F; Pfaller MA; Messer SA; Jones RN Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755 [TBL] [Abstract][Full Text] [Related]
9. Growth medium effect on the antifungal activity of LY 303366. Klepser ME; Ernst EJ; Ernst ME; Pfaller MA Diagn Microbiol Infect Dis; 1997 Dec; 29(4):227-31. PubMed ID: 9458979 [TBL] [Abstract][Full Text] [Related]
10. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Green LJ; Marder P; Mann LL; Chio LC; Current WL Antimicrob Agents Chemother; 1999 Apr; 43(4):830-5. PubMed ID: 10103187 [TBL] [Abstract][Full Text] [Related]
11. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. Espinel-Ingroff A J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049 [TBL] [Abstract][Full Text] [Related]
12. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Ernst EJ; Klepser ME; Ernst ME; Messer SA; Pfaller MA Diagn Microbiol Infect Dis; 1999 Feb; 33(2):75-80. PubMed ID: 10091029 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Uzun O; Kocagöz S; Cetinkaya Y; Arikan S; Unal S Antimicrob Agents Chemother; 1997 May; 41(5):1156-7. PubMed ID: 9145888 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Krishnarao TV; Galgiani JN Antimicrob Agents Chemother; 1997 Sep; 41(9):1957-60. PubMed ID: 9303393 [TBL] [Abstract][Full Text] [Related]
15. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Zhanel GG; Saunders DG; Hoban DJ; Karlowsky JA Antimicrob Agents Chemother; 2001 Jul; 45(7):2018-22. PubMed ID: 11408217 [TBL] [Abstract][Full Text] [Related]
16. Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration. Majoros L; Kardos G; Szabó B; Sipiczki M Antimicrob Agents Chemother; 2005 Aug; 49(8):3486-8. PubMed ID: 16048965 [TBL] [Abstract][Full Text] [Related]
17. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents. Zhanel GG; Karlowsky JA; Zelenitsky SA; Turik MA; Hoban DJ Antimicrob Agents Chemother; 1998 Sep; 42(9):2446-8. PubMed ID: 9736582 [TBL] [Abstract][Full Text] [Related]
18. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Nguyen KT; Ta P; Hoang BT; Cheng S; Hao B; Nguyen MH; Clancy CJ Antimicrob Agents Chemother; 2009 Aug; 53(8):3347-52. PubMed ID: 19364856 [TBL] [Abstract][Full Text] [Related]
19. Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3. Varga I; Sóczó G; Kardos G; Majoros L J Antimicrob Chemother; 2008 Jul; 62(1):149-52. PubMed ID: 18390882 [TBL] [Abstract][Full Text] [Related]
20. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Klepser ME; Ernst EJ; Lewis RE; Ernst ME; Pfaller MA Antimicrob Agents Chemother; 1998 May; 42(5):1207-12. PubMed ID: 9593151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]